MAXITROL

This brand name is authorized in United States. It is also authorized in Brazil, Canada, Croatia, Ecuador, Estonia, Finland, Hong Kong SAR China, Ireland, Israel, Lithuania, Mexico, New Zealand, Nigeria, Poland, Romania, Singapore, Spain, Tunisia, UK.

Active ingredients

The drug MAXITROL contains a combination of these active pharmaceutical ingredients (APIs):

1	Neomycin UNII 057Y626693 - NEOMYCIN SULFATE
	Neomycin is an aminoglycoside antibiotic and acts by binding to polysomes, inhibiting protein synthesis and generating errors in the transcription of the genetic code.
	Read more about Neomycin
2	Polymyxin B UNII 19371312D4 - POLYMYXIN B SULFATE
	Polymixin B is bactericidal against a wide range of gram negative bacilli. It exerts a bactericidal effect by binding to acid phospholipids in the cell wall and membranes of the bacterium, thereby rendering ineffective the osmotic barrier normally provided by the cell membrane.
	Read more about Polymyxin B
3	Dexamethasone UNII 7S5I7G3JQL - DEXAMETHASONE
	Dexamethasone is a synthetic glucocorticoid; it combines high anti-inflammatory effects with low mineralocorticoid activity. It has an approximately 7 times greater anti-inflammatory potency than prednisolone, another commonly prescribed corticosteroid. At high doses it reduces the immune response.
	Read more about Dexamethasone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MAXITROL Eye drops, suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01CA01	Dexamethasone and antiinfectives	S Sensory organs → S01 Ophthalmologicals → S01C Antiinflammatory agents and antiinfectives in combination → S01CA Corticosteroids and antiinfectives in combination
Discover more medicines within S01CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	500902601166312, 500902602170313
CA	Health Products and Food Branch	00042676, 00358177
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1072-MEE-0615, 25.910-09-04
EE	Ravimiamet	1124301
ES	Centro de información online de medicamentos de la AEMPS	42610, 5730-2005-01, PL00649-5915R
FI	Lääkealan turvallisuus- ja kehittämiskeskus	486886
GB	Medicines & Healthcare Products Regulatory Agency	14965, 43787
HK	Department of Health Drug Office	16912, 17041
HR	Agencija za lijekove i medicinske proizvode	HR-H-013807789, HR-H-641598573
IE	Health Products Regulatory Authority	73105
IL	מִשְׂרַד הַבְּרִיאוּת	3246, 742
LT	Valstybinė vaistų kontrolės tarnyba	1012840, 1012841, 1066138, 1077966, 1078906, 1078907, 1085353, 1085793, 1087839
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	63496, 64134
NG	Registered Drug Product Database	04-1570, A4-1744
Switch country to Nigeria in order to find specific presentations of MAXITROL
NZ	Medicines and Medical Devices Safety Authority	945, 946
PL	Rejestru Produktów Leczniczych	100042165, 100046170, 100079441, 100132336, 100257701, 100257753, 100257990, 100260809, 100265882, 100283443, 100288593, 100324840, 100343205, 100360853, 100360988, 100365508, 100383334, 100393657, 100398991, 100406029, 100406874, 100421537, 100426300, 100455218, 100458049, 100458277, 100458596, 100460302, 100460310, 100467943
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63598001
SG	Health Sciences Authority	04358P
TN	Direction de la Pharmacie et du Médicament	10283441
US	FDA, National Drug Code	0065-0631, 0078-0771, 0998-0630